Comment je fais l’IRM et le score VI-RADS d’une tumeur de vessie ?

L. Dernis1, G. Marcq2,3, D. Seguier2, P. Puech1,4
1CHU de Lille, service d’imagerie génito-urinaire et hématologique, hôpital Claude-Huriez, 59000 Lille, France
2CHU de Lille service d’urologie, hôpital Claude-Huriez, 59000 Lille, France
3CNRS, Inserm, CHU Lille, institut Pasteur de Lille, UMR9020-U1277–CANTHER–Cancer heterogeneity plasticity and resistance to therapies Lille, France
4Université Lille, Inserm, U1189 research lab, 59000 Lille, France

Tài liệu tham khảo

Rouprêt, 2018, RETRACTED : recommandations françaises du comite de cancérologie de l’AFU — Actualisation 2018—2020: tumeurs de la vessie, Prog En Urol, 28, S46, 10.1016/j.purol.2018.07.283 Panebianco, 2018, Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System), Eur Urol, 74, 294, 10.1016/j.eururo.2018.04.029 Metwally, 2021, The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study, Eur Radiol [Internet], 10.1007/s00330-021-07765-5 Barchetti, 2019, Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center, Eur Radiol, 29, 5498, 10.1007/s00330-019-06117-8 Necchi, 2020, Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study, Eur Urol, 775, 636, 10.1016/j.eururo.2019.12.016